Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Short term Debt (2016 - 2026)

Insight Molecular Diagnostics' Short term Debt history spans 7 years, with the latest figure at $428000.0 for Q4 2025.

  • On a quarterly basis, Short term Debt rose 87.72% to $428000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $428000.0, a 87.72% increase, with the full-year FY2025 number at $428000.0, up 87.72% from a year prior.
  • Short term Debt hit $428000.0 in Q4 2025 for Insight Molecular Diagnostics, down from $1.1 million in the prior quarter.
  • Over the last five years, Short term Debt for IMDX hit a ceiling of $2.6 million in Q1 2021 and a floor of $109000.0 in Q3 2022.
  • Historically, Short term Debt has averaged $806555.6 across 5 years, with a median of $611500.0 in 2022.
  • Biggest five-year swings in Short term Debt: tumbled 92.73% in 2022 and later skyrocketed 2022.94% in 2023.
  • Tracing IMDX's Short term Debt over 5 years: stood at $1.4 million in 2021, then crashed by 92.15% to $109000.0 in 2022, then skyrocketed by 2022.94% to $2.3 million in 2023, then plummeted by 90.15% to $228000.0 in 2024, then soared by 87.72% to $428000.0 in 2025.
  • Business Quant data shows Short term Debt for IMDX at $428000.0 in Q4 2025, $1.1 million in Q3 2025, and $689000.0 in Q2 2025.